Endometrial Cancer Panel by NGS + dMMR by IHC near me in Asansol

The Endometrial Cancer Panel by Next-Generation Sequencing (NGS) is a cutting-edge genetic testing approach that delves deep into the molecular landscape of endometrial cancer. This panel screens for genomic alterations in 31 genes associated with endometrial cancer, while also examining mutations in key genes like POLE, TP53, and MMR genes. 

This comprehensive panel offers a multitude of benefits. Firstly, it plays a pivotal role in delivering precise and accurate diagnoses, prognoses, and therapy recommendations for patients across all stages of endometrial cancer, including recurrent cases. Additionally, it sheds light on the genetic basis of endometrial cancer, identifying potential germline origins through the analysis of genes like BRCA1, BRCA2, and MMR pathway genes.

Furthermore, the panel covers tumor-agnostic biomarkers, including BRAF, RET, NTRK1, NTRK2, and NTRK3, which have approved targeted therapies applicable to various metastatic solid tumors. This holistic approach to genetic testing empowers healthcare providers with valuable insights to tailor treatment strategies, offering new hope and possibilities for patients battling endometrial cancer.

Immunohistochemistry (IHC) for DNA Mismatch Repair (dMMR) plays a critical role in diagnosing endometrial cancer. It involves the assessment of specific proteins - MLH1, MSH2, MSH6, and PMS2 - to determine their nuclear expression. When all MMR proteins are intact, indicating no loss of expression, it suggests a low probability of microsatellite instability-high (MSI-H). However, the loss of expression of specific proteins indicates potential issue and aids in tailoring treatment and assessing the risk of hereditary cancer syndromes in endometrial cancer patients.

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.